Mannkind Corporation (NASDAQ: MNKD) is a small company based in Valencia, California, focusing on the development and commercialization of medicine to treat diabetes. Mannkind's lead drug, Afrezza, was FDA approved on June 27, 2014, as treatment indication for patients with both Type 1 and Type 2 diabetes. The company's proprietary Technosphere is a novel drug delivery system that enabled Afrezza, super rapid acting insulin, to be delivered through a small whistle like device called the Dreamboat immediately prior to mealtime.
- Warning! GuruFocus has detected 3 Warning Signs with MNKD. Click here to check it out.
- MNKD 15-Year Financial Data
- The intrinsic value of MNKD
- Peter Lynch Chart of MNKD
Unlike Mr. Market, who had been consistently wrong regarding Afrezza's advisory committee (ADCOM) votes, trials data, and the FDA final approval, I am highly optimistic regarding the drug's commercial success. Moreover, I hope to elucidate and clarify Afrezza superiority over needles injection through the lenses of a physician, patient advocates, researcher, and research analyst.
Despite needles being ultra thin these days, problems associated with prolonged use like inconvenience, scarring, stigma, and psychological fear persist. To self-administered injection, patients usually have to be excused to the bathroom. This does not bode well in modern society, one that is evolving toward increasing technological advancement. As a rule-of-thumb, a successful products necessitates user's friendliness and convenience.
In contrast to injections, Afrezza was ingeniously designed with unparalleled simplicity and convenience. By simply inhaling Afrezza through a tiny inconspicuous Dreamboat, patients could easily have insulin immediately available before mealtime to optimize blood sugar control. Diabetes would be easily as long as blood sugar is well controlled.
It is important to note that tissue scarring indeed occur with prolonged needle-use due to the needle breaking up collagen in subcutaneous tissue, and our body natural tendency to reestablish the tissue's integrity. Also, many patients who just started injection tend to make injecting mistakes that amplify scarring. The needle's aesthetic unappealing hinders patient's compliance, thus, explaining such high rates of diabetes complications.
Though pain associated with injections is real, the psychological anticipation of pain is more painful. This anticipation of pain persists, even if we could develop needles thinner than our hair that are technically "painless." Hence, patients who have not been on insulin injection, commonly referred to as "insulin-naïve" by physicians, would favor Afrezza over conventional insulin injections.
It is imperative for investors to note, needles stigma is real. When using needles in public for insulin injection, patients would fear being labeled as "junkies" and other colorful names. This social pressure has particularly strong impacts on patients with Type 1 diabetes, who tend to be teenage patients. Stigma is a powerful deterrence, hindering patient's compliance, and causing patients to lose their sight, limbs, kidneys, as well as, increasing the risks of heart diseases and hampering the body natural ability to heal itself.
In my prior work as an MD, I witnessed diabetes complications and its devastation not only to the patients but also to their family. Diabetes complications also have consequential economic ramifications as the annual spending tallied up to $245 billion. Hence, it would be reasonable for politicians, clinicians, and advocates to support Afrezza from the economic viewpoint.
Pertaining to the medical and scientific perspectives, conventional rapid acting insulin like Humolog and Novolog do not exhibit the same kinetics as Afrezza. The competitive edge for Afrezza is its super rapid acting pharmacokinetics, enabling it to mimic the action of the natural human pancreas. Hence, this clearly distinguished Afrezza from all competitors ... even the commonly mentioned inhale insulin, Exubera, which is delivered through a bong, because Exubera only exhibits regular RAA kinetics. Furthermore, Afrezza super rapid acting property would enable the drug to work faster, allowing patients to use insulin immediately prior to mealtime, having insulin exiting the body quicker, thus, minimizing the dreaded complication of hypoglycemia.
Nonetheless, Afrezza comes with the price exhibiting slightly less A1c – a marker of how well diabetes is controlled – reductions but it's insignificant when assessing the big picture. Prescribers like doctors, NP, or PA could always increase the prescribing dose of the basal insulin, as Lantus or Levemir, to achieve optimal hemoglobin A1c while enjoying the freedom from hypoglycemia, stigmatization, inconvenience, and tissue scarring.
My informal surveying of physician colleagues and patients indicated that the medical community would highly welcome Afrezza market entry. For instance, patients from "Better Health," which is a nonprofit diabetes support group, were fascinated with the story on Afrezza.
Regarding physicians prescribing pattern, personal preferences and more importantly patient's preferences indeed play significant roles. After all, a medically effective treatment would be obsolete if it does not win the patient's heart. It appeared that the overwhelming majority of patients highly favored Afrezza, forecasting the revolutionary drug's path toward being a blockbuster. Furtheremore, an independent research firm conducted surveys of physicians last year, also, revealed evidence of overwhelming physicians' support for Afrezza.
The bottom line is that Afrezza demonstrates characteristics of a potential blockbuster in the making, but Mr. Market is quoting Mannkind shares in the mid $9, which is highly undervalued versus comparative market analysis valuation of $38 per share. As Afrezza hit the market with increasing success, echoing stories from Main Street physicians and patients, Wall Street will quote the stock at significant premium than its current shares price. According to the Illustrious Investor Peter Lynch, it pays to bet against the pessimistic Mr. Market, as well as, to practice due diligence, patience, and conviction.
Readers could access 360 Biotech research articles on Mannkind by clicking on the referenced links below:
- A Featured Presentation On Mannkind Corporation's Revolutionary Diabetes Treatment
- Transcending Traditional Security Analysis, Integrated Investing Research Shed Light On Mannkind Corporation True Value
- In Al We Trust
- Amidst Buyout And Partnership Anticipation - Mannkind Is In Good Hands
- Where's Mannkind Heading After The Historical Event Of Afrezza FDA Approval
- FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's Investigational Drug to Treat Diabetes
- Mannkind Shareholders Focus On These Facts Rather Than Weekend Worrying
- Why Rising Obesity Means Blockbuster Revenue For Afrezza
- Mannkind Corporation: Catalyzing The Next Revolution In Diabetes Treatment
- Mannkind Corporation: The Potential Revolutionary Treatment For Diabetes Delivering Value For Shareholders
- Integrated Investing Research: Doctor Tran’s Top Quarterly